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Abstract
Purpose The purpose of this study is to investigate the phar-
macokinetics and deep tissue penetration capability of the
newly developed S-flurbiprofen plaster (SFPP) in humans.
Methods Study 1: SFPP tape-type patch (2–60 mg) was ap-
plied to the lower back for 24 h in healthy adult volunteers. S-
flurbiprofen (SFP) plasma concentration was measured over
time to examine SFP pharmacokinetics.
Study 2: SFPP (20 mg) was applied for 12 h to the affected
knee of osteoarthritis (OA) patients who were scheduled for
total knee arthroplasty. Deep tissues (synovial tissue and sy-
novial fluid) were collected during surgery to compare SFP
concentrations after application of SFPP or a commercially
available flurbiprofen (FP) gel-type patch.
Results Study 1: The plasma concentration of SFP was
sustained during 24-h topical application of the SFPP, show-
ing a high percutaneous absorption ratio of 51.4–72.2%. Cmax
and AUC0-∞ were dose-proportional.
Study 2: After application of the SFPP for 12 h, SFP con-
centrations in the synovial tissue and synovial fluid were 14.8-
fold (p = 0.002) and 32.7-fold (p < 0.001) higher, respectively,
than those achieved by the FP patch.
Conclusions Sustained plasma concentration of SFP and high
percutaneous absorption ratio was observed after 24-h topical
application of the SFPP. Compared to the FP patch, the SFPP
showed superior percutaneous absorption and greater tissue
penetration of SFP into the synovial tissue. Greater tissue pen-
etration of the SFPP seemed to be primarily due to its formu-
lation. Thus, SFPP is expected to show higher efficacy for the
treatment of knee OA.
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Introduction
Major symptoms of osteoarthritis (OA) are chronic pain and
functional disorder derived from synovitis, both of which sub-
stantially decrease the quality of life of afflicted patients [1, 2].
Oral and topical nonsteroidal anti-inflammatory drugs
(NSAIDs) have been widely used to treat the symptoms of
OA and such use is recommended by various guidelines
[3–5].
Because pain severity in OA patients is associated with the
degree of synovitis [6, 7], it is important to confirm the drug
concentration in synovial tissue when predicting the therapeu-
tic effect of topical NSAIDs [8, 9]. Therefore, drug concentra-
tions in knee joint tissue after application of topical NSAIDs
have been determined [8–13].
We developed a new generation topical NSAID patch, the
S-flurbiprofen plaster (SFPP). S-flurbiprofen (SFP) is an en-
antiomer of racemic flurbiprofen (FP), and SFP potently
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inhibits cyclooxygenase (COX)-1 and COX-2, whereas the
corresponding inhibitory effects of R-flurbiprofen (RFP) are
extremely weak [14, 15]. The commercially available gel-type
FP patch, which consists of a water-soluble polymer and wa-
ter, has low percutaneous absorption and relative bioavailabil-
ity of about 4 % of that of the oral tablet [16]. The SFPP was
developed in the form of a tape-type patch, consisting of a
hydrophobic polymer without water, and SFP dissolved in
minimal amount of solvent, to achieve highly improved per-
cutaneous absorption and superior penetration into deep tis-
sue. In animal studies, the SFPP produced high percutaneous
absorption, penetration into deep inflammatory tissue, analge-
sic activity, and anti-inflammatory activity (submitted).
The present studies were aimed at elucidating the plasma
pharmacokinetics and deep tissue penetration of the SFPP in
humans. First, the pharmacokinetic profile of the SFPP after a
single application to the lower back of healthy adult volun-
teers was examined (study 1). Next, concentrations of SFP in
deep tissues (synovial tissue and synovial fluid) were exam-
ined in patients with knee OA scheduled for total knee
arthroplasty and compared to those produced by a gel-type
FP patch which contains the same amount of SFP and is com-
mercially available in European companies, South Africa, and
Japan for many years (study 2).
Methods
Test patches
SFPP tape-type patches containing 2, 5, 10, and 20mg of SFP,
placebo patches containing no SFP, and FP gel-type patches
(Stayban®) containing 40 mg of FP were manufactured by
Tokuhon Corporation (Tokyo, Japan). With the limitation of
solubility of SFP, maximum SFP content was limited to 20mg
per patch (size 7 cm × 10 cm).
Study design
Study 1: pharmacokinetic study in healthy volunteers
The study protocol was approved by the Institutional Review
Board (IRB) of the Bio-Iatoric Center at Kitasato Institute
(Tokyo, Japan) and conducted at the Bio-Iatoric Center at
Kitasato Institute. The study was conducted according to the
Declaration of Helsinki and GoodClinical Practice guidelines.
Healthy adult male volunteers aged 20–35 years were includ-
ed in the study. Those who had skin wounds, acne, or other
abnormalities at the site of application (lower back) and those
who had used any other drug within the week prior to the
application of the study drug were excluded from the study.
SFPP tape-type patches (7 cm × 10 cm), containing 2, 5,
10, or 20 mg of SFP, were used in this study. To evaluate 6
dose regimens (2, 5, 10, 20, 40, and 60 mg), one sheet of 2-,
5-, 10-, or 20-mg patches was applied for the 2–20 mg dose
regimens, whereas 2 and 3 sheets of 20-mg patches were
applied for the 40-mg and 60-mg dose regimens, respectively.
A placebo patch containing no SFP was also used as the com-
parator for safety evaluation.
After written consent was obtained, 30 healthy male vol-
unteers were enrolled in a randomized, single-blinded, place-
bo-controlled, dose-escalation phase 1 study. Each subject
was applied two times at the interval of 2 weeks. The subjects
were allocated to 3 groups of 10 persons each and were ran-
domly given the SFPP (n = 7) or placebo (n = 3) at two steps
(group 1 2 mg/5 mg; group 2 10 mg/20 mg; group 3 40 mg/
60 mg) (Fig. 1).
The SFPP or placebo patch was applied to the lower back
for 24 h. Blood samples were collected 1 h before application
and at 2, 4, 6, 8, 10, 12, 14, 24, 28, 32, 36, 47, and 71 h after
application (5 mL on each occasion). The collected blood
samples were centrifuged immediately. Plasma samples were
stored at approximately −20 °C until SFP concentrations were
measured. The applied patches were collected to calculate the
percutaneous absorption ratio.
Study 2: tissue concentration study for knee OA
The study protocol was approved by the IRB of Eniwa Hos-
pital (Hokkaido, Japan), and the study was conducted at
Eniwa Hospital. The study was conducted according to the
Declaration of Helsinki and GoodClinical Practice guidelines.
The study included patients with knee OA scheduled for
unilateral total knee arthroplasty. Patients who had a history of
surgery (excluding arthroscopic-assisted surgery) of the target
knee and those who had received FP or undergone arthroscop-
ic examination, centesis, or drainage of the target knee within
7 days prior to the application of the study drug were
excluded.
SFPPs (10 cm × 14 cm), containing 20 mg of SFP, were
used in the study. The comparator FP patch was the Stayban®
pap (10 cm × 14 cm) gel-type patch containing 40 mg of FP.
The SFP content was identical (20 mg) in the tested patches.
Twenty patients who gave written consent were included in
this randomized open-label, parallel group comparative study.
SFPPs and FP patches were cut in half (7 cm × 10 cm) and
applied to the target knee at a site about 2 cm distant from the
intended incision line on the right and left sides. SFPPs and FP
patches were applied to 10 patients each, after which the SFP
concentration in deep tissue of the knee and safety were
evaluated.
The patches were applied for 12 h, which approximated
tmax on the basis of the pharmacokinetic parameters of the
FP patch [17] and the pharmacokinetic parameters of the
SFPP determined in a single application study (study 1). Each
patch was removed just before surgery. Synovial tissue,
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synovial fluid, and plasma were collected at the time of sur-
gery and stored at approximately −20 °C until SFP concentra-
tions were measured. The applied patches were collected to
calculate the percutaneous absorption ratio.
Analytical methods
Study 1
The SFP concentrations in the plasma and patches were deter-
mined by high-performance liquid chromatography (HPLC)
at Sumika Chemical Analysis Service, Ltd. (Osaka, Japan).
The validated SFP plasma concentration range was 2–
800 ng/mL, intra-run precision was ≤4.8 %, and intra-run
accuracy was −6.2 to 10.0 %. The validated SFP concentra-
tion range in a sheet of the patch was 0.2–25 mg, with intra-
run precision of ≤2.4 % and intra-run accuracy of −9.5 to
5.0 % (further details are provided in supplementary
documents).
Study 2
The SFP concentrations in tissue and plasma were determined
by liquid chromatography and mass spectrometry (LC-MS/
MS) and the SFP and FP concentrations in the patches were
determined by HPLC at Taisho Pharmaceutical Co., Ltd. (To-
kyo, Japan). The validated SFP concentration range was 5–10,
000 ng/g for synovial tissue and 0.5–1000 ng/mL for synovial
fluid and plasma. Intra-run precision and intra-run accuracy
were ≤3.3 % and −2.5 to 6.1 % for synovial tissue, ≤ 4.4 %
and −4.6 to 1.7 % for synovial fluid, and ≤4.7 % and 1.2 to
11.6 % for plasma. The range of validated drug concentrations
in a patch sheet was 8–48 mg of SFP for the SFPP and 22.4–
40mg of FP for the FP patch. Intra-run precision and intra-run
accuracy were ≤0.6 % and −0.4 to 1.6 % for the SFPP and
≤0.3 % and 0.9 to 1.9 % for the FP patch (further details are
provided in supplementary documents).
Pharmacokinetic analysis
Pharmacokinetic parameters were calculated as follows. Cmax
and tmax were obtained directly from the plasma concentra-
tion. The elimination rate constant (λz) was obtained by log-
linear regression of the terminal phase of the plasma
concentration-time curve. The t1/2 was calculated as ln2/λz.
AUC0-∞ was calculated as the sum of the area from time zero
to the last quantifiable time point t obtained by the trapezoidal
method, and the area from t to infinite time calculated fromCt/
λz; Ct is the last observed quantifiable concentration.
The percutaneous absorption ratio was calculated from the
SFP amount in the patch (A) and the residual amount in the
used patch (B) according to the following equation:





Descriptive statistics for plasma concentrations, pharmacoki-
netic parameters, and absorption were calculated by dose
group. Dose proportionality for Cmax and AUC0-∞ was evalu-
ated by determining whether the two-sided 95 % confidence
Table 1 Subject demographics (study 1)
Group 1 Group 2 Group 3
2 mg (n = 7) 5 mg (n = 7) 10 mg (n = 7) 20 mg (n = 6) 40 mg (n = 7) 60 mg (n = 7)
Age (years) 23.0 ± 3.7 22.9 ± 2.5 22.3 ± 2.1 22.5 ± 1.9 24.1 ± 3.3 23.3 ± 2.3
(20–30) (20–26) (20–26) (21–26) (21–30) (21–26)
Weight (kg) 61.01 ± 8.07 61.93 ± 8.36 63.89 ± 6.70 61.48 ± 7.55 58.54 ± 4.37 60.39 ± 6.73
(53.0–74.7) (51.4–74.7) (54.8–72.9) (54.4–72.9) (53.1–66.6) (50.4–70.7)
BMI (kg m−2) 21.19 ± 2.07 21.06 ± 2.48 21.45 ± 1.95 20.97 ± 2.27 20.06 ± 0.82 20.25 ± 1.15
(18.9–24.9) (17.7–24.9) (19.1–24.4) (18.6–24.4) (19.2–21.7) (18.7–21.7)
Mean ± SD (range)
Fig. 1 Flow chart of study 1
Eur J Clin Pharmacol (2016) 72:53–59 55
intervals (CI) of regression coefficient estimates for these pa-
rameters did or did not include 1 using the power model.
Study 2
All analyses were carried out using SAS® 9.1.3. Statistical
comparisons between groups were made using Welch’s t test
because it could be assumed that the absorption ratios
achieved by the SFPP and FP patches were quite different.
Therefore, below-the-limit-of-quantification (BLQ) data was
imputed using the lower limit of quantification (LLOQ;
5.0 ng g−1 for synovial tissue and 0.500 ng mL−1 for synovial
fluid and plasma) when the concentration was BLQ, to avoid
skewing the results for the FP patch. The significance level
was set at 5 % (two-sided).
Results
Study 1
In this study, 32 healthy adult volunteers (a cumulative total of
58 subjects at all steps in group 1, group 2, and group 3) were
examined (Fig. 1). Table 1 shows the demographics of the
subjects (cumulative total, 41) in whom the plasma SFP con-
centration was determined after application of the SFPP.
Themean plasma concentrations vs. time profiles and phar-
macokinetic parameters of SFP are shown in Fig. 2 and
Table 2, respectively. The tmax and t1/2 values for the plasma
SFP concentration were 10.3–17.7 h and 7.6–8.4 h, respec-
tively. The percutaneous absorption ratio, determined based
on the residual amount of SFP in the patch, was 51.4–72.2 %.
The dose proportionality of Cmax and AUC0-∞ was exam-
ined using a power model. Table 3 shows the regression co-
efficients (95 % CI) of Cmax and AUC0-∞ at the dose range 2–
20 mg, 20–60 mg, and 2–60 mg. For 2–20 mg, only the SFP
content in the patches were different. For 20–60 mg, only the
number of patch was different which means the application
area was enlarged to increase the dose. The 95 % CI in each
range includes 1, showing dose proportionality, respectively.
In addition, although the application area and the SFP content
of the patches were different, dose proportionality was con-
firmed at the dose range of 2–60 mg.
With regard to safety, cutaneous symptoms were the major
adverse reactions found at the site of topical application in the
SFPP (36.6 %, 15/41 subjects) and placebo groups (41.2 %,
7/17 subjects). Mild erythema was the most common cutane-
ous symptom (72.7 %, 16/22 subjects) and recovered prompt-
ly without any treatment.
Study 2
This study included 20 patients with knee OA scheduled for
total knee arthroplasty. One patient was excluded from phar-
macokinetic analysis due to the prior use of the patch
Table 3 Regression coefficients (95 % CI) of Cmax and AUC0−∞
Dose range (mg) Regression coefficients (95 % CI)
Cmax AUC0-∞
2–201 1.0175 (0.9154–1.1197) 1.0483 (0.9564–1.1402)
20–602 0.9042 (0.6437–1.1647) 0.8719 (0.5926–1.1513)
2–60 0.9679 (0.9076–1.0282) 0.9910 (0.9303–1.0517)
1 One sheet of 2-, 5-, 10-, or 20-mg patches
2 1, 2, and 3 sheets of 20-mg patches
Table 2 Pharmacokinetic parameters and absorption ratios of SFP after topical application of the SFPP (24 h)
2 mg (n = 7) 5 mg (n = 7) 10 mg (n = 7) 20 mg (n = 6) 40 mg (n = 7) 60 mg (n = 7)
Cmax (ng mL
−1) 43.3 ± 7.1 114.5 ± 20.3 248.0 ± 63.5 444.1 ± 120.3 858.2 ± 235.8 1187.7 ± 294.6
tmax (h) 13.7 ± 7.2 15.1 ± 6.2 10.3 ± 1.4 14.7 ± 4.7 17.7 ± 6.0 16.3 ± 5.3
t1/2 (h) 8.3 ± 0.9 7.8 ± 1.2 7.8 ± 1.1 8.4 ± 0.5 8.4 ± 1.1 7.6 ± 0.4
AUC0-∞ (ng mL
−1 h) 1051.0 ± 156.7 2801.4 ± 414.2 6055.8 ± 1422.8 11,705.3 ± 3054.3 23,129.8 ± 7854.7 30,236.9 ± 7429.7
Absorption ratio (%) 61.2 ± 10.7 68.0 ± 12.4 72.2 ± 10.5 64.1 ± 10.5 57.5 ± 9.3 51.4 ± 7.9
Mean ± SD
Fig. 2 Plasma concentrations of SFP (mean + SD, log scale) vs. time
profiles 24 h after topical application of the SFPP (2 mg (white circle),
5 mg (filled circle), 10 mg (white triangle), 20 mg (filled triangle), 40 mg
(white square), and 60 mg (filled square))
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containing FP, which was prohibited. The subject demo-
graphics of each group are shown in Table 4.
Table 5 shows the SFP concentrations in each tissue and
absorption ratios after topical application. Because the syno-
vial fluid could not be collected in one of the subjects in the
SFPP group, the calculation included 9 subjects. The SFP
concentration in synovial tissue after application of the FP
patch was BLQ in 8 of 9 subjects. Therefore, the LLOQ
(5 ng g−1) was used in the calculation according to the statis-
tical analysis plan.
The SFP concentrations in synovial tissue, synovial fluid,
and plasma after topical application of the SFPP were signif-
icantly higher (p < 0.05) than those achieved by the FP patch,
with mean values 14.8-, 32.7-, and 34.5-fold higher, respec-
tively. The percutaneous absorption ratio of the SFPPwas also
significantly higher (p < 0.05) than that of the FP patch, with a
mean value 7.6-fold higher.
With regard to safety, there were no adverse reactions in
either group.
Discussion
Plasma SFP concentrations in healthy adult volunteers after a
single topical application of the SFPP for 24 h were dose
proportional and sustained throughout the topical application
period. The results showed that the SFPP has a favorable
pharmacokinetic profile allowing once-daily application.
The formulation of topical NSAIDs is known to greatly
affect their percutaneous absorption [18]. The SFPP and FP
patch showed marked differences in percutaneous absorption
and tissue penetration, which were likely primarily due to
differences in the patch formulations. The SFPP is a tape-
type patch, whereas the FP patch is a gel-type patch. It is
presumed that high concentrations of lipophilic SFP dissolved
in the patch (consisting of a hydrophobic polymer) contribut-
ed to the high percutaneous absorption and tissue penetration
achieved by the SFPP. In addition, medium-chain fatty acid
ester, a penetration enhancer [19], was used as an additive in
the SFPP and may have contributed to the observed improve-
ment in percutaneous absorption.
Bolten reported the FP concentrations in synovial fluid and
serum after topical application of a gel-type FP patch in pa-
tients who required surgery for knee OA and orthopedic dis-
ease [10]. The reported data are tissue concentrations of FP;
the ratio of SFP concentration to RFP concentration is unclear.
However, considering that the ratio of SFP Cmax to RFP Cmax
after oral administration of FP was 1.05 [20], and there was no
chiral inversion of enantiomers [21], the SFP concentration
was estimated as half of the FP concentration. According to
this estimation, the SFP concentrations in synovial fluid and
plasma 12 h after topical application of the FP patch in our
study were similar to those reported by Bolten.
Cmax and AUC0-∞ after oral administration of SFP 50mg in
gelatin capsule were reported as 9.3 μg mL−1 and
55.2 μg h mL−1, respectively [21]. As dose proportionality
was observed in the SFPP, Cmax and AUC0-∞ after application
of the SFPP 50 mg could be proportionally calculated from
those of the SFPP 40 mg and 60 mg as 1.0 μg mL−1 and
26.7 μg h mL−1. The pharmacokinetic parameters ratios
(SFP oral administration/SFPP) are approximately 9 for Cmax
and 2 for AUC0-∞, which mean smaller values are observed in
the SFPP. It was reported that the plasma concentration after
repeated application of FP patch was 2.5 times higher than that
after single application [16]. So it must be important to study
the pharmacokinetics after repeated application of SFPP.
Table 5 SFP concentrations in
each tissue type and absorption
ratios after topical application of
the SFPP or FP patch (12 h)
SFFP (n = 10) FP (n = 9) P value
Synovial tissue (ng g−1) 84.5 ± 56.0 (44.5, 125) 5.70 ± 2.10a (−)a 0.002
Synovial fluid (ng mL−1) 149 ± 44.9b (114, 183) 4.55 ± 3.66 (1.74, 7.37) <0.001
Plasma (ng mL−1) 362 ± 84.8 (302, 423) 10.5 ± 10.1 (2.74, 18.3) <0.001
Absorption ratio (%) 44.46 ± 10.63 (36.85, 52.07) 5.82 ± 1.64 (4.56, 7.08) <0.001
Mean ± SD (95 % CI)
LLOQ, 5.0 ng g−1 for synovial tissue and 0.500 ng mL−1 for synovial fluid and plasma
a Eight samples of synovial tissue (FP) contained SFP below the limit of quantitation, so 5.0 ng g−1 (LLOQ) was
used to calculate the mean and SD (95 % CI was not calculated)
b n = 9 (one subject’s synovial fluid could not be collected)
Table 4 Subject demographics (study 2)
SFPP (n = 10) FP (n = 9)
Male/female 1/9 0/9
Age (years) 72.2 ± 6.4 72.0 ± 6.8
(60–80) (59–78)
Weight (kg) 69.23 ± 15.77 62.53 ± 3.66
(42.7–102.8) (57.1–69.3)
BMI (kg m−2) 29.74 ± 5.38 28.51 ± 1.67
(23.0–41.2) (26.1–31.0)
Mean ± SD (range)
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In this study, we measured SFP concentrations in synovial
tissue and synovial fluid at a single time point around tmax
(12 h after topical application), without conducting measure-
ments at other time points. Because plasma SFP concentra-
tions were similar 12 and 24 h after topical application of the
SFPP for 24 h, it is speculated that the SFP concentrations in
synovial tissue and synovial fluid persist in the same manner
as the plasma SFP concentration.
In conclusion, topical application of the SFPP for 24 h
provided a persistent high plasma concentration of SFP in a
dose-proportional manner. In addition, the SFP concentrations
in synovial tissue and synovial fluid after application of the
SFPP, as well as the percutaneous absorption ratio of SFP,
were significantly higher than those after application of the
FP patch. It is expected that the SFPP may exert a potent
anti-inflammatory and analgesic effect by achieving penetra-
tion of a high concentration of SFP into deep synovial tissue,
the site of inflammation in patients with knee OA.
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